264 related articles for article (PubMed ID: 23931953)
21. Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease.
LeWitt PA; Boroojerdi B; MacMahon D; Patton J; Jankovic J
Clin Neuropharmacol; 2007; 30(5):256-65. PubMed ID: 17909303
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson's disease.
Hauser RA; Slawek J; Barone P; Dohin E; Surmann E; Asgharnejad M; Bauer L
BMC Neurol; 2016 Jun; 16():90. PubMed ID: 27267880
[TBL] [Abstract][Full Text] [Related]
23. Rotigotine Transdermal Patch Does Not Make Parkinson Disease Patients Sleepy During Daytime.
Ohta K; Osada T
Clin Neuropharmacol; 2015; 38(6):231-5. PubMed ID: 26536020
[TBL] [Abstract][Full Text] [Related]
24. Spotlight on rotigotine in Parkinson's disease.
Baldwin CM; Keating GM
Drugs Aging; 2008; 25(2):175-7. PubMed ID: 18257604
[TBL] [Abstract][Full Text] [Related]
25. Rotigotine transdermal patch: a review of its use in the treatment of Parkinson's disease.
Sanford M; Scott LJ
CNS Drugs; 2011 Aug; 25(8):699-719. PubMed ID: 21790211
[TBL] [Abstract][Full Text] [Related]
26. Allergic contact dermatitis caused by rotigotine in a transdermal therapeutic system.
Raison-Peyron N; Guillot B
Contact Dermatitis; 2016 Aug; 75(2):121-2. PubMed ID: 27385523
[No Abstract] [Full Text] [Related]
27. Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K; Lyons KE
Pharmacotherapy; 2009 Dec; 29(12):1452-67. PubMed ID: 19947805
[TBL] [Abstract][Full Text] [Related]
28. Drug safety evaluation of rotigotine.
Sprenger FS; Seppi K; Poewe W
Expert Opin Drug Saf; 2012 May; 11(3):503-12. PubMed ID: 22468676
[TBL] [Abstract][Full Text] [Related]
29. Rotigotine Transdermal Patch for Motor and Non-motor Parkinson's Disease: A Review of 12 Years' Clinical Experience.
Raeder V; Boura I; Leta V; Jenner P; Reichmann H; Trenkwalder C; Klingelhoefer L; Chaudhuri KR
CNS Drugs; 2021 Feb; 35(2):215-231. PubMed ID: 33559846
[TBL] [Abstract][Full Text] [Related]
30. Rotigotine: Parkinson's disease: a step backward.
Prescrire Int; 2008 Apr; 17(94):60. PubMed ID: 18516813
[TBL] [Abstract][Full Text] [Related]
31. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease.
Watts RL; Jankovic J; Waters C; Rajput A; Boroojerdi B; Rao J
Neurology; 2007 Jan; 68(4):272-6. PubMed ID: 17202432
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of rotigotine transdermal patch for the treatment of depressive symptoms in patients with Parkinson's disease.
Chung SJ; Asgharnejad M; Bauer L; Ramirez F; Jeon B
Expert Opin Pharmacother; 2016 Aug; 17(11):1453-61. PubMed ID: 27322571
[TBL] [Abstract][Full Text] [Related]
33. Effect of using a wearable device on clinical decision-making and motor symptoms in patients with Parkinson's disease starting transdermal rotigotine patch: A pilot study.
Isaacson SH; Boroojerdi B; Waln O; McGraw M; Kreitzman DL; Klos K; Revilla FJ; Heldman D; Phillips M; Terricabras D; Markowitz M; Woltering F; Carson S; Truong D
Parkinsonism Relat Disord; 2019 Jul; 64():132-137. PubMed ID: 30948242
[TBL] [Abstract][Full Text] [Related]
34. Wearing off, dyskinesia, and the use of continuous drug delivery in Parkinson's disease.
Jenner P
Neurol Clin; 2013 Aug; 31(3 Suppl):S17-35. PubMed ID: 23931952
[TBL] [Abstract][Full Text] [Related]
35. Steady-state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-label, randomized, phase I multiple dose studies.
Elshoff JP; Braun M; Andreas JO; Middle M; Cawello W
Clin Ther; 2012 Apr; 34(4):966-78. PubMed ID: 22401642
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics, safety and tolerability of rotigotine transdermal patch in healthy Japanese and Caucasian subjects.
Cawello W; Kim SR; Braun M; Elshoff JP; Ikeda J; Funaki T
Clin Drug Investig; 2014 Feb; 34(2):95-105. PubMed ID: 24178238
[TBL] [Abstract][Full Text] [Related]
37. Rotigotine for the treatment of Parkinson's disease.
Morgan JC; Sethi KD
Expert Rev Neurother; 2006 Sep; 6(9):1275-82. PubMed ID: 17009915
[TBL] [Abstract][Full Text] [Related]
38. Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson's disease: an open-label study.
Kim JM; Chung SJ; Kim JW; Jeon BS; Singh P; Thierfelder S; Ikeda J; Bauer L;
BMC Neurol; 2015 Feb; 15():17. PubMed ID: 25879416
[TBL] [Abstract][Full Text] [Related]
39. Rotigotine transdermal delivery for the treatment of Parkinson's disease.
Rascol O; Perez-Lloret S
Expert Opin Pharmacother; 2009 Mar; 10(4):677-91. PubMed ID: 19239399
[TBL] [Abstract][Full Text] [Related]
40. Rotigotine transdermal patch in Chinese patients with early Parkinson's disease: A randomized, double-blind, placebo-controlled pivotal study.
Zhang ZX; Shang HF; Hu X; Chen S; Zhao Z; Du X; Surmann E; Bauer L; Asgharnejad M
Parkinsonism Relat Disord; 2016 Jul; 28():49-55. PubMed ID: 27172830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]